Very recently, niclosamide has been shown to increase the efficacy of PD-1/PD-L1 immune checkpoint by the blockage of phosphorylated STAT3 to the promoter of PD-1 [18], opening new possibilities for cancer immunotherapy through targeting STAT3 [19]. This evidence concerns the gene STAT3 and cancer.